SCHEMBL22845227

SCHEMBL22845227

COc1ccc(CN2CCc3c(n4ncc(Cc5ccccc5)c4n(-c4ccccc4)c3=O)C2)cc1OC

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GNRHR P30968 3/20 0.44
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
GAA P10253 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
TP53 P04637 1/20 0.40
CLPP Q16740 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TAAR1 Q96RJ0 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 1/20 0.39
REV1 Q9UBZ9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22845269 0.95 GNRHR (0.43) GNRHRKMT2AMEN1GAAL3MBTL1
SCHEMBL22845204 0.89 GNRHR (0.44) GNRHRKMT2AMEN1GAAL3MBTL1
SCHEMBL22845483 0.87 GNRHR (0.44) GNRHRKMT2AMEN1GAAL3MBTL1
SCHEMBL22845374 0.84 GNRHR (0.45) GNRHRKMT2AMEN1GAAL3MBTL1
SCHEMBL22845403 0.83 TP53 (0.45) GNRHRKMT2AMEN1TP53ALDH1A1
SCHEMBL22845489 0.83 GNRHR (0.44) GNRHRKMT2AMEN1GAAL3MBTL1
SCHEMBL24470066 0.81 ALDH1A1 (0.39) KMT2AMEN1GAAKDM4EALDH1A1
SCHEMBL22845396 0.80 GNRHR (0.44) GNRHRKMT2AMEN1GAAL3MBTL1
SCHEMBL22845307 0.77 CLPP (0.47) GNRHRKMT2AMEN1GAAL3MBTL1
SCHEMBL22845219 0.72 HTR2C (0.39) GNRHRKMT2AMEN1TP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220000874-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2022-01-06 US disclosed
US-11136321-B2 Tricyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2021-10-05 US disclosed
US-20200407361-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2020-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220000874-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL GNRHR 2198/4885KMT2A 3917/4885MEN1 274/4885
US-11136321-B2 Tricyclic compounds SLC10A1, PKD1, CEL GNRHR 2198/4885KMT2A 3917/4885MEN1 274/4885
US-20200407361-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL GNRHR 2198/4885KMT2A 3917/4885MEN1 274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.